Oppenheimer Reiterates Their Hold Rating on Globus Medical

By Ryan Adsit

Oppenheimer analyst Steven Lichtman reiterated a Hold rating on Globus Medical (NYSE: GMED) today. The company’s shares closed yesterday at $28.28.

According to TipRanks.com, Lichtman is ranked 0 out of 5 stars with an average return of -5.2% and a 51.5% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Integra Lifesciences.

Globus Medical has an analyst consensus of Moderate Buy, with a price target consensus of $32.50.

Globus Medical’s market cap is currently $2.72B and has a P/E ratio of 25.48. The company has a book value ratio of 3.0079.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Globus Medical, Inc. is a medical device company, which engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C.